


# Pyxant Labs Bolsters Capabilities in Acquisition of Covance by Labcorp's SLC Bioanalytical Site



Innovative bioanalytical CRO Pyxant Labs' solutions advance leading-edge and challenging drug development programs from translation through NDA approval. Leveraging granular knowledge of the bioanalytical laboratory market, Crosstree assisted Pyxant in the negotiation, funding, and execution of a unique opportunity to expand their capabilities with the acquisition of Covance by Labcorp's Salt Lake City Bioanalytical site. The transaction strengthens Pyxant's business on all fronts, including differentiated capabilities in large molecule bioanalysis.

Crosstree played an integral role in assisting Pyxant with securing the acquisition opportunity with Covance and tailoring a targeted and accelerated process to evaluate private equity financing options to both recapitalize Pyxant's shareholder base and finance the acquisition. Crosstree's ability to effectively convey the merits of the combination led to strong private equity interest concluding with the selection of ArchiMed, a European healthcare investor with unique capabilities to support Pyxant in its growth initiatives.

**Our goal is to match specialized companies with those of complementary technology, strategy, and synergies.**

## ABOUT PYXANT LABS



Pyxant Labs is a contract research laboratory specializing in bioanalytical chemistry development support for life sciences clients. Founded in 2000, Pyxant Labs utilizes advanced bioanalytical technologies to support preclinical and clinical pharmaceutical development programs, drawing upon the Company's core strengths: Superior scientific expertise, validated regulatory expertise, on time delivery, and anticipatory customer service.

## ABOUT COVANCE BY LABCORP



Covance by Labcorp's Salt Lake City Bioanalytical Site provides comprehensive bioanalytical services to the pharmaceutical and biotech industry in support of early-stage discovery studies through NDA submission. The site is recognized as an industry leader in the bioanalytical support of RNA therapeutics utilizing high resolution mass spectrometry, traditional LC-MS/MS, and UPLC/fluorescence detection platforms.

## ABOUT ARCHIMED



ArchiMed is a leading private equity firm focused exclusively on the healthcare industry, serving as a strategic and financial partner to European and North American small and middle-market businesses in targeted segments of healthcare.

## CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Superior positioning of client-specific strengths and synergy opportunities
- Access to a worldwide network of key strategic and financial decision-makers
- Exceptional analytics cultivated over a 17-year exclusive commitment to Health Sciences
- Dedicated senior-level professionals with deep expertise in Health Sciences
- Track record of tailoring bespoke processes with high success rates

All while prioritizing corporate core values.

## MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's [proven track record](#) of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



**JEFF ELLIS, CFA**

Co-Founder &  
Managing Director

[jeff.ellis@crosstreecapital.com](mailto:jeff.ellis@crosstreecapital.com)  
813-774-4753